-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $39

Benzinga·05/26/2026 15:59:58
Listen to the news
Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $39.